Widely-Used BP Pill Jolts Cancer Playbook

A close-up view of a variety of colorful pills and tablets stacked together

A cheap, decades-old blood pressure pill may help a cutting-edge cancer drug kill tumors it normally cannot touch — and the science behind that claim is more solid than most headlines let on.

Quick Take

Dartmouth Cancer Center researchers found that telmisartan, a common blood pressure drug, dramatically boosted the power of olaparib, a cancer drug, in lab and animal studies published July 2025.
Telmisartan was the only blood pressure drug of its type that worked this way — the effect appears unique to this specific drug, not the whole drug family.
The combination worked by triggering the body’s own immune system to attack tumors, using a pathway called STING.
Two Phase I clinical trials are now recruiting real patients — one for prostate cancer, one for ovarian cancer — but human proof of benefit does not yet exist.

What Researchers Actually Found at Dartmouth

A team led by Dr. Tyler Curiel at Dartmouth Cancer Center published a peer-reviewed study in the Journal for ImmunoTherapy of Cancer on July 9, 2025. The study tested telmisartan — a widely used, inexpensive blood pressure pill — alongside olaparib, a cancer drug in a class called PARP inhibitors (poly ADP-ribose polymerase inhibitors). PARP inhibitors work by blocking a protein cancer cells use to repair their own damaged DNA. The idea was simple: could telmisartan make olaparib hit harder?

The answer, in the lab at least, was yes — and in a surprising way. Telmisartan did not just add to olaparib’s punch. It triggered a specific immune alarm inside tumor cells called the STING (Stimulator of Interferon Genes) pathway. That alarm signals the body to flood the tumor with type I interferon proteins, which call immune cells to attack. The combination also stripped tumors of a protective shield called PD-L1, a protein that normally tells the immune system to stand down. Remove that shield, and the immune system fights harder.

Why This Drug and Not the Others Like It

Telmisartan belongs to a drug family called angiotensin II receptor blockers (ARBs). Doctors prescribe ARBs every day for high blood pressure. The Dartmouth team tested several ARBs to see if any of them could replicate what telmisartan did. None could. Losartan, valsartan, and the others showed no meaningful synergy with olaparib. This matters because it rules out a simple “blood pressure drug” effect. Something specific about telmisartan’s chemistry is doing the work. That narrows the science and, frankly, makes it more credible.

The Biggest Practical Promise — Tumors Without the Usual Weakness

PARP inhibitors like olaparib already work well in patients whose tumors carry BRCA gene mutations. Those mutations leave cancer cells unable to repair DNA properly, making them sitting ducks for olaparib. The problem is that most tumors do not have BRCA mutations. Telmisartan appears to make those “normal” tumors vulnerable to olaparib anyway, by forcing DNA damage through a different route. If that holds up in humans, the pool of patients who could benefit from PARP inhibitors would expand enormously.

Two Clinical Trials Are Now Recruiting Patients

Dartmouth Hitchcock Medical Center is leading a Phase I trial (trial number NCT06168487) testing telmisartan in men with metastatic prostate cancer. A second Phase I trial (NCT06815497) is testing the combination in women with platinum-resistant ovarian cancer, with progression-free survival listed as a primary goal. Phase I trials focus on safety and tolerability first. They are not designed to prove the drug cures cancer. That proof, if it comes, will require Phase II and Phase III trials with far more patients and longer follow-up periods.

What the Science Cannot Promise Yet

Every cancer-killing result in this study came from lab dishes and mice. Mouse immune systems differ from human ones in important ways, and drug combinations that look powerful in animals fail in humans more often than they succeed. The STING pathway that makes telmisartan work may not be active in all tumor types, which means the drug likely will not help everyone. The prostate cancer trial also only tracks tolerability for 60 days — there is no long-term safety data yet for cancer patients who do not have high blood pressure taking this drug.

The Media Got Ahead of the Science — But the Science Is Still Worth Watching

Headlines calling telmisartan a drug that makes cancer therapy “far more powerful” use language the data does not fully support yet. Dr. Curiel himself was careful, saying the drug “may significantly improve” how well PARP inhibitors work — not that it does. That hedge matters. The history of oncology is full of drug combinations that dazzled in the lab and disappointed in the clinic. The honest read here is that the mechanism is genuinely novel, the drug is cheap and already approved for another use, and the early science is strong enough to justify human trials. That is meaningful. It is just not a cure yet.